Similar findings have been reported with other CSF1R inhibitors to treat models of multiple sclerosis (42, 70, 90) demyelination (91–94), Alzheimer’s disease (36, 44, 91, 95, 96) neuroinflammation and neurodegeneration (36, 37, 44). Here, CSF1R is linked to multiple sclerosis.